8-KLeadership ChangesOther EventsExhibits & Filings

DEXCOM INC 8-K Report, Executive Changes (Oct 13, 2020)

Filed October 13, 2020For Securities:DXCM

Summary

DexCom, Inc. (DXCM) filed an 8-K on October 13, 2020, to announce a significant addition to its Board of Directors. The company elected Kyle Malady as a Class II director, effective October 11, 2020. Mr. Malady's appointment fills a vacancy and is expected to strengthen the board's expertise. He has been deemed an independent director by the company and Nasdaq listing standards. In line with DexCom's compensation policies for non-employee directors, Mr. Malady received an initial grant of restricted stock units (RSUs) valued at $500,000, which will vest over three years. He is also set to receive customary annual compensation in the form of RSUs valued at $300,000 in 2021. This appointment and compensation structure are designed to align Mr. Malady's interests with those of DexCom shareholders and ensure experienced leadership oversight.

Key Highlights

  • 1DexCom appointed Kyle Malady as a new Class II director to its Board of Directors.
  • 2Mr. Malady's appointment became effective on October 11, 2020.
  • 3The company has confirmed Mr. Malady qualifies as an independent director.
  • 4Mr. Malady will receive an initial restricted stock unit (RSU) grant valued at $500,000 upon appointment, vesting over three years.
  • 5He is also eligible for a customary annual RSU grant valued at $300,000 in 2021.
  • 6The RSU grants are part of DexCom's standard director compensation policy and align with the 2015 Equity Incentive Plan.
  • 7The appointment was announced via a press release furnished as an exhibit to the 8-K filing.

Frequently Asked Questions

Kyle Malady has been elected as a new Class II director to DexCom's Board of Directors. His appointment fills a vacancy and is intended to enhance the board's governance and strategic oversight. The filing does not specify his prior background beyond confirming he is an independent director.

Upon his appointment, Mr. Malady received an initial grant of restricted stock units (RSUs) valued at $500,000, which will vest over a three-year period. He will also receive an annual grant of RSUs valued at $300,000 in 2021 as part of the standard compensation for non-employee directors.

The filing explicitly states there are no arrangements or understandings between Mr. Malady and any other persons regarding his selection as director. Furthermore, he is not a party to any material transactions with DexCom that would require disclosure under Item 404(a) of Regulation S-K, and he has been determined to be an independent director.

Mr. Malady will hold office until the 2022 Annual Meeting of DexCom's stockholders, which is the next meeting where Class II directors will be elected.